On the other hand, some studies have shown that FGFR-3 is not overexpressed in benign prostatic hyperplasia as well as in prostate cancer itself [55–57] corroborating our results that showed that the levels of this receptor decrease with the advancement of this malignant disease. This evidence concerns the gene FGFR3 and benign prostatic hyperplasia.